rs759933264
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_006517.5(SLC16A2):c.538G>A(p.Val180Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000148 in 1,210,501 control chromosomes in the GnomAD database, including 2 homozygotes. There are 64 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 12/18 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_006517.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC16A2 | ENST00000587091.6 | c.538G>A | p.Val180Ile | missense_variant | 2/6 | 1 | NM_006517.5 | ENSP00000465734.1 | ||
SLC16A2 | ENST00000636771.1 | n.*239G>A | non_coding_transcript_exon_variant | 3/7 | 5 | ENSP00000490445.1 | ||||
SLC16A2 | ENST00000636771.1 | n.*239G>A | 3_prime_UTR_variant | 3/7 | 5 | ENSP00000490445.1 | ||||
SLC16A2 | ENST00000590447.1 | c.-24G>A | upstream_gene_variant | 5 | ENSP00000466213.1 |
Frequencies
GnomAD3 genomes AF: 0.000481 AC: 54AN: 112289Hom.: 1 Cov.: 23 AF XY: 0.000668 AC XY: 23AN XY: 34441
GnomAD3 exomes AF: 0.000327 AC: 60AN: 183483Hom.: 1 AF XY: 0.000280 AC XY: 19AN XY: 67919
GnomAD4 exome AF: 0.000114 AC: 125AN: 1098160Hom.: 1 Cov.: 31 AF XY: 0.000113 AC XY: 41AN XY: 363514
GnomAD4 genome AF: 0.000481 AC: 54AN: 112341Hom.: 1 Cov.: 23 AF XY: 0.000667 AC XY: 23AN XY: 34503
ClinVar
Submissions by phenotype
Spastic paraplegia Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 30, 2023 | - - |
Inborn genetic diseases Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 15, 2018 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
not provided Benign:1
Likely benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at